Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the As…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
Procter & Gamble to acquire Thorne for $3.8 billion, CEO says Investing.com -- Procter & Gamble Co. reached an agreement to acquire supplement maker Thorne for $3.8 billion, with the deal set to be announced later today. | ||
ACCO vs. HLN: Which Stock Is the Better Value Option? ACCO vs. HLN: Which Stock Is the Better Value Option? | ||
Haleon PLC (HLN) (H1 2026) Earnings Call Highlights: Organic Growth Improves, North America ... Haleon PLC (HLN) delivers sequential organic sales growth of 3.1% in Q2, with strong North America and emerging market performance offsetting persistent respiratory weakness. | ||
Sensodyne maker Haleon slips as sales growth concerns overshadow profit beat July 30 (Reuters) - Sluggish European demand and weak respiratory sales raised doubts on Thursday about whether Haleon can meet its sales targets, sending shares in the consumer health company lower despite better-than-expected first-half profit. The British maker of Theraflu and Flonase cold medicines and Sensodyne toothpaste reported first-half organic revenue growth of 2. | ||
Haleon H1 Earnings Call Highlights Haleon (NYSE:HLN) said its second-quarter organic sales growth accelerated to 3.1% from 2.2% in the first quarter, supported by improved execution in North America, continued growth in emerging markets and a stronger contribution from pain relief and oral health products. Chief Executive Officer Br | ||
Haleon slides as quality of growth questioned Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 2.9% to 368.7p after the consumer healthcare group reported improving second-quarter sales but left its full-year guidance unchanged. Organic revenue increased 3.1% in the second quarter, split between 1.7% from pricing and 1.4% from volumes and... | ||
Is Kenvue Stock Attractive After Margin Gains and Deal Uncertainty KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced. | ||
Kenvue Benefits From Consumer Health Trends and Margin Expansion Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility. | ||
Haleon (HLN) Partners with Microsoft (MSFT) to Advance Digital and AI Capabilities Haleon (NYSE:HLN) is one of the best up and coming stocks to invest in right now. On June 1, Haleon announced a five-year collaboration with Microsoft (NASDAQ:MSFT) to scale its digital, data, and AI capabilities. This partnership aims to accelerate the company’s global “Win as One” strategy by integrating Microsoft’s cloud and AI tools into […] | IInsider Monkey | |
Haleon Signs a Five-Year Agreement With Microsoft (MSFT) to Deploy Agentic AI Across Its Global Operations Microsoft Corporation (NASDAQ:MSFT) is one of the top stocks to buy according to Whale Rock Capital Management. On June 29, Haleon, a consumer health company, announced a new five-year collaboration with Microsoft Corporation (NASDAQ:MSFT) to expand the use of cloud, data, and artificial intelligence tools across Haleon’s global operations. Haleon said the deal builds on […] | IInsider Monkey | |